What is Shuttle Pharmaceuticals?
Shuttle Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on enhancing treatment outcomes for cancer patients undergoing radiation therapy. The company's pipeline includes novel therapeutic drugs and diagnostic tools aimed at increasing the efficacy of radiation therapy while minimizing harm to healthy tissues. Lead candidates are designed to sensitize cancer cells to radiation and protect surrounding healthy tissue, alongside blood-test diagnostics to personalize patient treatment plans. These advancements aim to improve cure rates, extend survival, and elevate the quality of life for individuals battling serious malignancies.
How much funding has Shuttle Pharmaceuticals raised?
Shuttle Pharmaceuticals has raised a total of $863K across 2 funding rounds:
Debt
$73K
Other Financing Round
$790K
Debt (2021): $73K with participation from PPP
Other Financing Round (2024): $790K, investors not publicly disclosed
Key Investors in Shuttle Pharmaceuticals
PPP
Public-Private Partnership
What's next for Shuttle Pharmaceuticals?
The recent major strategic investment signifies a critical phase for Shuttle Pharmaceuticals, likely enabling the company to advance its clinical trials, expand its research and development capabilities, and potentially scale its operations. This enterprise-level backing suggests confidence from investors in the company's technology and its potential to disrupt the oncology market, particularly in radiation therapy. Future developments may include further clinical validation, strategic partnerships, and regulatory submissions, positioning Shuttle Pharma to address unmet needs in cancer care.
See full Shuttle Pharmaceuticals company page
